Clinical Trial Update: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Almonertinib as first-line treatment for EGFR-mutant advanced non-small cell lung cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING